INK4a has been identified in urothelial malignancies both cytologically and histologi- was significantly shorter for dual-labeled cases versus cases with negative dual labeling (P < .0001). The same tendency was observed in patients with histologically proven LGUN (P < .0001). As for specificity in patients with negative cystoscopy and cytology combined, prolonged follow-up showed 90% overall survival at 24 months. CONCLUSIONS: A longterm evaluation of p16/Ki-67 dual labeling may identify HGUC and progression in cases with negative/low-grade urinary cytology results, and there are potential implications for the clinical management of patients after the conservative treatment of non-muscle-invasive urothelial carcinoma.
INTRODUCTION
The p16 (INK4a) gene, located on chromosome 9p21, is also known as CDKN2A. Overexpression of the p16
INK4a protein has been documented in almost all preneoplastic and carcinomatous lesions of the uterine cervix secondary to interference between the E6 and E7 oncoproteins of high-risk papillomaviruses with the retinoblastoma (Rb) gene product. 1, 2 In urothelial carcinomas, p16 INK4a is most often undetectable 3, 4 as it is reported in many nongynecologic carcinomas. 5, 6 Homozygote deletions, methylation of 5 0 CpG islands, and mutations of CDKN2A have been reported as possible causes of a loss of p16 INK4a expression. [7] [8] [9] [10] Conversely, p16 overexpression has been reported in urothelial lesions, [11] [12] [13] particularly in 80% of high-grade tumors and approximately 100% of carcinoma in situ cases. 14, 15 In those cases, overexpression of the p16 INK4a protein can be explained by 1) alterations of the Rb gene in 13q14 (loss or methylation), 16 2) mutations with amplification of the 6p22 locus (E2F transcription factor gene) and inactivation of Rb, 17 3) chromosome 9 polysomy with amplification of the 9p21 locus, 14 and 4) accumulation of mutated inactive p16
INK4a with permanent phosphorylation of the Rb protein and progression in the cell cycle.
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p16/Ki-67 Dual Labeling
Simultaneous detection of p16 INK4a overexpression and
Ki-67 expression in the same tumor cell indicates deregulation of the cell cycle because under normal conditions, when a tumor-suppressive gene and a proliferation marker are co-expressed, they should exclude each other. In cervical cytopathology, p16 INK4a has been shown to highlight rare abnormal cells in the Papanicolaou slides of women with atypical squamous cells of undetermined significance (ASCUS) or low-grade squamous intraepithelial lesions (LSILs). 18 Moreover, p16 INK4a and Ki-67 dual labeling has been shown to provide increased sensitivity and specificity for the detection of underlying high-grade cervical intraepithelial lesions (cervical intraepithelial neoplasia 21) in women with ASCUS or LSILs. 19 The good results obtained in cervical cytopathology would prove useful if they were transferable to urinary cytology, where a significant proportion of diagnostic reports are dubious, atypical, or suspicious. [20] [21] [22] In previous studies, 23, 24 we have shown that in the urine, p16/Ki-67 could help to identify highgrade cancer cells in new patients with symptoms and in patients followed after the conservative treatment of bladder cancer. Cases were recorded between 2007 and 2012 and were followed until the end of 2012. In both groups of patients, a high-grade urothelial malignancy could be predicted by dual labeling in cases with negative/low-grade cytology results after a 9-to 11-month delay. 24 In the current study, we extended the follow-up period through 2016 with the goal of examining whether the time would allow additional life-threatening (high-grade) and progression cases to be identified.
The Paris System for Reporting Urinary Cytology (TPS)
As stressed by Murphy, 25 "the positive predictive value of urinary cytology used for the follow-up of patients with high-grade lesions is 80% to 90%"; it is not 100%. Some urinary cytology reports remain falsely negative, particularly during the follow-up period of conservatively treated patients (eg, after bacille Calmette-Gu erin [BCG] immunotherapy); this has stimulated for years the search for assays that could reduce individual test failures as much as possible. In addition, the need for a consensual, widely acceptable way of reporting urinary cytology results has been recognized for years. Following the work of the committees and consensus group that gathered after the 2013 International Congress of Cytology, which was held in Paris, the International Academy of Cytology and the American Society of Cytopathology published TPS in late 2015. 26 Because the main purpose of urinary cytology is the recognition of high-grade urothelial carcinoma (HGUC), TPS clearly delineates those cases that are negative for high-grade urothelial carcinoma (NHGUC). It also defines the contours of equivocal, atypical urinary cytology cases that are now subclassified as atypical urothelial cells (AUC) or suspicious for high-grade urothelial carcinoma (SHGUC). The low-grade urothelial neoplasia (LGUN) category is maintained as a separate entity, but it is advised to use it "sparingly." 27 To date, only a few publications have addressed the impact of TPS on daily laboratory performance or on the clinical management of patients. 28, 29 Because of the known overexpression of p16 INK4a in high-grade urothelial lesions, the cell cycle default that is theoretically highlighted by p16/Ki-67 dual labeling, and the potential impact of TPS, the current study was undertaken to investigate whether urine cytology on one hand or p16/Ki-67 on the other hand could help to better classify urothelial lesions and assess the risk of progression to a high grade, infiltration, or upper urinary tract (UUT) extension.
To reach these objectives, we collected previously dual-labeled cases that were reclassified according to TPS and followed for more than 36 months. We analyzed the association of the initial data with documented high-grade lesions and disease-free survival in every diagnostic category.
MATERIALS AND METHODS
A total of 208 urine samples taken after cystoscopy were collected from 184 patients referred for cystoscopy at the urology departments of the Centre Hospitalier Lyon Sud and Hôpital Edouard Herriot (Lyon, France). The study p16/Ki-67, Urinary Cytology, and Survival/Piaton et al
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protocol received a priori approval by the review committee of the Hospices Civils de Lyon. There were 33 female patients and 151 male patients (mean age, 71 6 13 years). Patients underwent consultation for symptoms (n 5 91) or were followed after complete transurethral resection (TUR), BCG immunotherapy, or surgery for lesions involving the bladder or the UUT. Exclusions are shown in Figure 1 .
Among the 117 previously treated cases, 55 (47.0%) previously had papillary urothelial neoplasia of low malignant potential (PUNLMP)/low-grade bladder lesions, and 57 (48.7%) previously had high-grade pTIS (n 5 12) or pTa-2 bladder tumors. One case had a previously operated squamous cell carcinoma of the bladder, and 4 (3.4%) had pTXGX bladder tumors.
The results of cystoscopy were recorded in all cases when they were available. TUR was performed for every case of papillary bladder lesion, whereas mucosal abnormalities suspicious for carcinoma in situ were evaluated with biopsies. Some patients underwent surgery for UUT tumors.
Urinary Cytology and Histopathology
Urine specimens were fixed with 50% Carbowax, which is a 20% poly(ethylene glycol) 1500 solution in 50% ethanol (Merck, Darmstadt, Germany). The samples were sent to the laboratory within 12 hours with clinical and cystoscopy data. After centrifugation (600g for 10 minutes), the cell pellet was suspended in a PreservCyt solution. After 30 minutes at room temperature, cells were centrifuged and resuspended in a 45-mL CytoLyt solution before being treated with the ThinPrep 2000 processor (Hologic Corp., Marlborough, Mass). Slides were stained with a hypochromic Papanicolaou procedure and embedded in a permanent mounting medium under coverslips. Cytologic results were all reviewed (E.P.) and reclassified according to TPS before analysis. Normal, inflammatory, reactive, and degenerative conditions of the urothelial component were considered NHGUC, as described by previous studies and actualized in TPS (2015). 26 INK4a and Ki-67 expression, respectively, defined a positive result (Fig. 2) . Cases without any doubleimmunoreactive cells were called negative for p16/Ki-67.
Analysis of the Data
All patients had histological controls after cystoscopy during a 0-to 6-month delay and were then followed for at least 36 additional months. Cystoscopy and urinary cytology were performed at every control according to the recommendations for follow-up of the European Association of Urology (http://www.uroweb.org). Progression was defined as recurrence at a higher stage or grade (TNM pTa-1 with a transition from G1/G2 to a higher grade, p16/Ki-67, Urinary Cytology, and Survival/Piaton et al
Cancer Cytopathology
July 2017 progression from pTa-1 to pT2 or higher, extension to the UUT, histologically documented metastases, or death from urothelial cancer 
RESULTS
Globally at consultation, there were 74 negative cystoscopy findings (including 12 cases with UUT tumors), 19 inflammatory or suspicious mucosal zones leading to bladder or urethral biopsies, and 94 typical papillary growths that were resected. In 21 cases (10.1%), cystoscopy results were not available. TUR, biopsy, and/or surgical specimens were obtained with a mean delay of 1.43 6 1.76 months (range, 0-6 months) after the initial evaluation. Overall, 128 tumors were histologically diagnosed (100 high-grade lesions, including 82 bladder tumors [2 were high-grade dysplastic lesions, and 15 were UUT tumors], and 28 PUNLMPs and low-grade urothelial carcinomas, including 3 UUT tumors). There were 20 negative histological controls (9.6%) in the whole series. Sixty cases (28.8%) had no histology; they included 47 cases (78.3%) with negative cystoscopy findings, 8 patients older than 88 years (who were not reviewed), 4 patients lost to follow-up, and 1 case of acute BCG-induced bladder inflammation.
Clinicopathologic Comparisons in the First
Period: 0 to 6 Months Urinary cytology, reclassified according to TPS, was negative (NHGUC) in 59 cases (28.4%), consistent with LGUN in 24 cases (11.5%), showed AUC in 15 cases (7.2%), was classified as SHGUC in 11 cases (5.3%), and was classified as HGUC in 99 cases (47.6%). Urinary cytology was classified as positive, high-grade, or SHGUC for 85 of 100 histologically proven high-grade lesions diagnosed during a 6-month delay (sensitivity for high-grade tumors, 85.0%). High-grade tumor cells were evidenced in 22 cases with negative histology (10.6% of the whole series), and they probably reflected urothelial lesions not yet confirmed at the initial follow-up consultation.
Positivity 
Extended Follow-Up and Disease-Free Survival
After the initial 0-to 6-month clinical evaluation, patients, particularly those with negative cystoscopy and urinary p16/Ki-67, Urinary Cytology, and Survival/Piaton et al
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July 2017 cytology results and those with PUNLMP/low-grade lesions, were followed for an additional period (mean, 31.13 6 16.11 months; range, 7-74 months). We particularly studied progression, which was defined as recurrence at a higher stage or grade, extension to the UUT, histologically documented metastases, or cancer-related death, as indicated in the Materials and Methods section. Against this background, urinary cytology findings were classified as positive, high-grade, or SHGUC for 102 of 122 cases of histologically proven high-grade lesions and progression or cancer-related death (Fig. 1) . Accordingly, the sensitivity of urinary cytology for life-threatening lesions, including SHGUC cases, was 83.6%.
According to urinary cytology results, p16/Ki-67 dual labeling occurred in 8.5% to 66.9% of cases (Fig. 1) .
Dual labeling was positive in 101 of 122 cases of histologically proven high-grade lesions and progression or cancerrelated death. Accordingly, the sensitivity of p16/Ki-67 for life-threatening lesions was not different from that of urinary cytology (82.8% vs 83.6%; OR, 0.9432; 95% CI, 0.45-1.95; P 5 1 [Fisher exact test]).
Kaplan-Meier curves comparing disease-free survival demonstrated that there was a significant difference (P 5 0; Fig. 3 ) between patients with negative urinary cytology results (including NHGUC, LGUN, and AUC cases) and patients with high-grade cytology results (HGUC and SHGUC cases). In the whole population, comparable results were obtained for cases with negative dual labeling and those with dual-labeled cells (P 5 0; Fig. 4) . Interestingly, among patients with negative cytology findings (NHGUC and AUC), disease-free survival was significantly shorter for cases with dual-labeled cells versus those with negative dual labeling (P < .0001; Fig. 5 ). The same tendency was observed in patients with histologically proven LGUN (P < .0001; Fig. 6 ). As for specificity in patients with negative cystoscopy and urinary cytology findings, after prolonged follow-up (23.85 6 19.96 months), there was 90% overall survival among 49 patients, including only 1 case (2.0%) with dual-labeled cells (Fig. 7) , who was unfortunately lost for control after 8 months of follow-up.
DISCUSSION
Urinary cytology is essentially intended to track HGUC lesions, including those that are not always viewed during Original Article cystoscopy because they can be located anywhere in the bladder, develop in flat mucosa, be associated with lowgrade papillary neoplasms, or originate from the UUT. 32 This somewhat restrictive, practical viewpoint has been recognized by TPS, which clearly delineates a body of cases that are NHGUC, atypical (AUC), or either suspicious for or typical of HGUC. Appropriately applied to the detection of HGUC lesions (those that can progress to muscle infiltration or metastases), urinary cytology most often achieves sensitivity values higher than 80% with a positive predictive value of approximately 90%. [33] [34] [35] [36] Inflammatory and reactive changes secondary to TUR, BCG immunotherapy, and intravesical chemotherapy may reduce the proportion of diagnostic cells and introduce diagnostic difficulties. Many urinary cytology reports are, therefore, categorized as suspicious, dubious, or atypical. Some authors have introduced the term AUC-US under the assumption that the meaning and use of AUC-US would be analogous to the ASCUS category used in gynecologic cytology. [37] [38] [39] Since the consensus of TPS (2015), the AUC-US category is now reported as AUC, with the reported rates of atypia ranging from 2% to 31%. 26 The new category of AUC has variable percentages of cases that will be malignant on follow-up: the risk of detecting histologically proven HGUC after AUC ranges from 8.3% to 37.5%. 39, 40 More useful probably is the new SHGUC category (previously recorded as AUC-H) because it has a subsequent histologically proven risk of HGUC ranging from 61.3% to 95% beyond 6 months of follow-up. 41, 42 In most precancerous and carcinomatous lesions of the uterine cervix, p16
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In gynecologic pathology, p16/Ki-67 dual labeling provides high sensitivity and specificity values for the detection of biopsy-confirmed high-grade lesions (cervical intraepithelial neoplasia 21) within a 6-month follow-up period in Papanicolaou smears initially categorized as ASCUS or LSIL. 19 In nongynecologic pathology, p16/Ki-67 has been little studied to date. We had already demonstrated that urothelial atypias (including AUC and SHGUC in the new TPS classification) preceded HGUC in 36.1% of cases within a mean interval of 10.5 6 12.0 months and that overall, atypias were associated with or predictive of HGUC in 73.8% of cases. 23, 24 Follow-up allowed cases of progression to be diagnosed in dual-labeled cases with negative/LGUN results after a 9-to 11-month delay. 23 We also showed that approximately 7.5% of cases with negative cystoscopy, negative cytology, and negative follow-up combined (mean delay, 10.4 months) were dual-labeled. 24 However, prolonged follow-up was lacking for testing the true prognostic significance of the p16/Ki-67 assay.
In the current study, the patient follow-up was divided into 2 periods to determine whether the diagnostic and prognostic evaluation of a urothelial malignancy might be influenced by cytology and/or p16/Ki-67 results: 1) the time necessary for preoperative histologic control of bladder or UUT urothelial disease (generally within 2 months) and 2) an extended follow-up period (31.13 6 16.11 additional months). Prolonged surveillance showed that among patients with negative urinary cytology (NHGUC and AUC) and patients with histologically proven LGUN, disease-free survival was significantly shorter for cases with dual-labeled cells versus those with negative dual labeling. As for specificity, it is interesting that among patients with concordant negative cystoscopy, negative urinary cytology, and negative dual labeling, the overall disease-free survival rate at 24 months was 90%.
The data obtained in this study suggest that p16/Ki-67 dual labeling could play more than a simple role as an adjunct to current surveillance strategies, including cystoscopy and urinary cytology. The American Urological Association and European Association of Urology guidelines recommend that urinary cytology be performed for highand low-risk patients with non-muscle-invasive tumor when it might defer the need for cystoscopy and UUT catheterization. 46 In light of the current study, p16/Ki-67 could help with identifying patients at risk of developing life-threatening lesions in NHGUC and AUC cases (Fig. 5) as well as LGUN cases ( Fig. 6 ; ie, all those that are cytologically negative for HGUC at the time of the evaluation). Because the purpose of urinary cytology is to detect lesions that are at higher risk for progression, it would be conceivable for a urologist to closely monitor these 2 categories of patients with repeated cystoscopy and biopsy, computed tomography, and UUT catheterization in cases in which dual labeling is positive.
In conclusion, a long-term evaluation of p16/Ki-67 dual labeling was shown to identify underlying HGUC and progression cases among patients with negative or lowgrade urinary cytology results, and there are potential implications for clinical management after the conservative treatment of non-muscle-invasive urothelial carcinoma.
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